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Abstract
Recent studies suggest that bone marrow stem cells (BMSCs) are promising grafts to treat a variety of diseases, including
reproductive dysfunction. Primary ovarian failure is characterized by amenorrhea and infertility in a normal karyotype
female, with an elevated serum level of follicle-stimulating hormone (FSH) and a decrease level of estrogen caused by a
mutation in FSH receptor (FSHR) gene. Currently, there is no effective treatment for this condition. The phenotype of FSHR
(2/2) mouse, FORKO (follitropin receptor knockout), is a suitable model to study ovarian failure in humans. Female FORKO
mice have elevated FSH, decreased estrogen levels, are sterile because of the absence of folliculogenesis, and display thin
uteri and small nonfunctional ovaries. In this study, we determined the effects of BMSC transplantation on reproductive
physiology in this animal model. Twenty four hours post BMSC transplantation, treated animals showed detectable
estroidogeneic changes in daily vaginal smear. Significant increase in total body weight and reproductive organs was
observed in treated animals. Hemotoxylin and eosin (H&E) evaluation of the ovaries demonstrated significant increase in
both the maturation and the total number of the follicles in treated animals. The FSH dropped to 40–50% and estrogen
increased 4–5.5 times in the serum of treated animals compared to controls. The FSHR mRNA was detected in the ovaries of
treated animals. Our results show that intravenously injected BMSCs were able to reach the ovaries of FORKO mice,
differentiate and express FHSR gene, make FSHR responsive to FSH, resume estrogen hormone production, and restore
folliculogenesis.
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Introduction
Hypergonadotropic hypogonadism accounts for up to 40% of
women with primary amenorrhea [1]. Many of these cases are due
to abnormalities of the sex chromosomes, such as Turner
syndrome. In normal karyotype females, hypergonadotropic
hypogonadism is a heterogeneous condition where the same
phenotype can have different etiologies [2]. The term ‘‘resistant
ovary syndrome’’ (ROS) is typically used to describe women with
primary or secondary amenorrhea, elevated circulating endoge-
nous FSH and luteinizing hormone (LH) levels, 46, XX karyotype,
intact uterus and vagina, absence of concomitant autoimmune
disease, and presence of numerous primordial follicles as evident in
ovarian biopsy [3]. This condition is a common cause of primary
ovarian failure [4] and is devastating for the patients who, besides
being infertile, will usually face an accompanying wide range of
physical and psychological problems. The possibility of achieving
spontaneous pregnancy is minimal. Ovulation stimulation with
human menopausal gonadotropin, as well as glucocorticoids
treatment, is unsuccessful in these patients [5]. There is currently
no effective treatment for this condition apart from symptomatic
management with hormone replacement therapy [3]. The sole
treatment option for these women is to achieve pregnancy through
in vitro fertilization using donated eggs. The resulting pregnancy
has to be supported by externally supplied hormones [3].
Histological examination of the ovaries of women with ROS
reveals a normal follicular milieu [6–8]. The follicles, however, are
arrested at the primordial stage because they cannot respond to
the FSH-enhancing effect. Laboratory assessment shows high
blood levels of FSH and low levels of estrogen. It has long been
suspected that the main physical defect in these women is an
abnormal FSH receptor that renders the ovaries insensitive or
resistant to the abundant FSH in the circulation, thus the name:
resistant ovary syndrome. Aittomaki et al. provided conclusive
evidence for this concept by identifying a C to T mutation at
nucleotide 566 of exon 7 of the FSHR gene located on
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residue 189 of the FSHR protein in these patients. Measurements
of cAMP suggests that this mutation greatly decreases the receptor
activity and subsequently leads to ovarian failure. The disorder is
heterogeneous with autosomal recessive mode of inheritance in
most cases [9] .To date, variable abnormalities of pubertal
development with primary or secondary amenorrhea in patients
with a partial or total loss of functional mutations in different
regions of the hFSHR gene have been reported [10–13]. Mice
carrying mutated FSHR gene, the so-called FORKO (follitropin
receptor knockout) mouse, is an appropriate animal model for
studying human hypergonadotropic ovarian dysgenesis and
infertility. Female FORKO mice display thin uteri, small ovaries,
elevated serum level of FSH, decreased estrogen level, and are
sterile because of the absence of folliculogenesis at the primary
stages [14]. We and other investigators have shown that a variety
of diseases, including reproductive dysfunction, can be treated by
bone marrow stem cells (BMSCs) [15–17]. The existence of
germline stem cells and the resultant ongoing follicle production in
the ovaries of postnatal mice has been reported by Johnson, et al.
2004 [18]. Based on gene expression analyses and bone marrow
transplantation (BMT) experiments using chemotherapy sterilized
recipients, Johnson et al. [19] showed in adult female mice that a
putative germline stem cells reservoir that supports oogenesis
appears to reside in the bone marrow (BM). Additional
transplantation studies using peripheral blood (PB) harvested from
transgenic females, with germline-restricted green fluorescent
protein (GFP) expression show that GFP-positive oocytes are
formed in chemotherapy-treated recipient females. This suggests
that putative germ cells in BM release progenitor cells into the
peripheral circulation that travel to the ovaries for oocyte
production [19]. Selesniemi et al. [16] showed that stem cell
transplantation prevents age-related infertility in adult female
mammals.
Here we show that adult bone marrow can be grafted into the
ovaries of knock-out mice for FSHR gene to restore estrogen
production, decrease FSH secretion, and promote folliculogenesis.
Materials and Methods
Animals
FSHR deficient mice (FSHR2/2) were generated as described
elsewhere [14]. Animals were housed in the Meharry Medical
College Animal Care Facility and provided food and water. The
Institutional Animal Use and Care Committee at Meharry
Medical College approved all procedures, (vide approval number
070824AAH318 on May 02, 2004 and August 07, 2007) including
animal care, euthanasia, and tissue collection. FSHR-deficient
(FORKO) mouse model was chosen to explore the possibility of
stem cell-derived somatic cells regeneration. A FORKO breeding
colony was established and all animals used in this work were
generated in that colony. FSHR +/2 mice were bred together and
offsprings were genotyped. Mice which were FSHR +/+, +/2 and
2/2 were obtained and used as donors and recipients in our
study. In other words, all mice used in this work were syngeneic
and hence we would not expect immunological reactions to the
transplantation process. Six to ten weeks old female mice served as
both treated and control animals.
Screening/genotyping of mice
Mice heterozygous for FSHR (FSHR +/2) were mated, and
offspring were genotyped to determine whether they were FSHR
(2/2), FSHR (+/2), or WT. Briefly, DNA was extracted from 3-
mm tail of tissue using the DNeasy tissue kit (QIAGEN, Valenica,
CA) according to manufacturer’s protocol. Extracted DNA was
subjected to PCR using the following primers: 1) 59-AAGG-
GACTGGCTGCTATTG-39,2 )5 9- AGAAAAGCGGCCATTT-
TC-39 set for mutated allele and 3) 59- AGTTCAATGGCG-
TTCCG-39,4 )5 9-CATGTCAGTAGTACATTAGAG-39 set for
normal allele. RED Taq Ready Mix PCR reaction containing
0.4 mM deoxynucleoside triphosphates (dNTPs), 20 mM Tris-
HCL, PH 8.3, with 100 mM KCl, 3 mM MgCl2, 0.002% gelatin,
stabilizers and 0.06 IU/ml Taq polymerase (Sigma Aldrich, St
Louis, MO) was used for PCR amplification in a total volume of
50 ml of reaction containing 100 ng template DNA and 150 ng
primers. PCR condition was set as a denaturation at 94uC for
5 min, followed by 30 cycles of 94uC for 45 sec, 56uC for 45 sec,
72uC for 1 min, and final extension at 72uC for 10 min. PCR
products were subjected to electrophoresis in 1% agarose gel and
visualized under UV light. Mice were genotyped based on the
presence of only WT band (+/+), only mutated band (2/2), or
both bands (+/2).
Bone marrow transplantation of treated and control
animals
Six to ten weeks old female mice were used as both treated and
control animals. Female FORKO mice were given a single tail
vein injection of BM collected from normal (+/+) adult syngeneic
female mice. Two different control groups were used in this study:
In the first group (2/2) mice were transplanted with BM cells
obtained from (2/2) mice and in the second control group (+/+)
mice were injected with BM cells from (2/2) mice. Bone marrow
was harvested from crushed femurs and tibias of wild-type or
(2/2) syngeneic female mice. In brief; animals were sacrificed;
tibia and femur were clipped to small pieces with scissors after
removing all muscles and connective tissues. Bone chips were
thoroughly rinsed with PBS/heparin in a 50 ml tube. The washed
solution containing bone marrow cells was transferred into a 50 ml
tube after filtration through a 70-mm nylon mesh filter, and
centrifuged at 1500 rpm for 5 min. The supernatant was aspirated
and 1 ml RBC lysing buffer was added to the pellet and gently
mixed for 1 min. To dilute the lysing buffer, 20 ml PBS was added
and centrifuged at 250–500 g for 7 min and then the supernatant
was discarded. The pellet was resuspended in complete medium.
The number of cells were counted using hematocytometer and 1–
2610
7 cells in 0.5 ml of PBS were injected into recipients
intravenously via the tail vein using standard procedures. After
BMT, females were mated with age-matched normal males at
different time points of the experiments for possible ovulation and
pregnancy during the experiments.
Daily vaginal smear and total body weight
After IV injection of the BM, treated and control animals were
weighed and tested on a daily basis for estrus cycles using vaginal
smears as described previously [20–21].
Tracking the donor cells
To track the donor cells, animals were sacrified from each group
and organ samples were used to extract DNA. We amplified DNA
from the treated and control groups by PCR, using the same
primer sets and conditions used for genotyping the animals as
mentioned above.
Injection of PMSG/hCG and evaluation of oviducts for the
release of oocytes and corpora lutea formation
Female mice in control and treated groups (six/group) were
subjected to an ovulation induction. Briefly, folliculogenesis was
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2.5 IU of pregnant mare serum gonadotropin (PMSG). Forty eight
hours post PMSG, ovulation was induced in each mouse with an
IP injection of 2.5 IU of human chorionic gonadotropin (hCG).
Subsequently, mice were sacrificed between 10–13 hours post
hCG by CO2 asphyxiation, following which uterus/oviduct
complexes were excised and trimmed of fat. Oviducts were
separated from the uterine horns with the aid of a dissecting
microscope and flushed with Dulbecco, supplemented with 0.1%
hyaluronidase (Sigma Chemical Co., St Louis, MO) that was
preincubated at 37uC, into a watch glass. Individual oviductal
flushing was examined with Nikon TMD inverted microscope at
4006magnification for the presence of ova.
Tissue preparation and follicular growth measurement
Animals were sacrificed at 1, 3, 6, 9 and 12-week time points,
after BMT, under anesthesia. Organ samples (brain, lung, heart,
liver, spleen, femur, adipose, ovary, uterus, vagina and cervix)
were collected, weighed and stored at 270uC until further
processing. All organs were weighed by blinded lab technician
who were not aware of control or treated animals. Organ weight
was calculated as the percentage of total body weight. The tissues
were fixed in 10% formalin overnight and embedded in paraffin.
Five-micrometer-thick sections were stained with hematoxylin and
eosin for light microscopic histological examination. To evaluate
follicular growth, follicles were classified as preantral if they
contained an oocyte with a visible nucleolus, more than one layer
but less than five layers of granulosa cells, and lacked an antral
space. Follicles were classified as antral if they contained an oocyte
with a visible nucleolus, more than five layers of granulosa cells,
and/or an antral space [22].
Hormone assays
Blood samples were collected from treated and control animals
before and after treatment. Serum FSH, luteinizing hormone
(LH), estrogen and progesterone levels were measured. FSH
measurements were determined by RIA using reagents provided
by Dr. A.F. Parlow and the National Hormone and Peptide
Program and procedures validated earlier [23]. Mouse FSH
reference prep was used for assay standards and Mouse FSH
antiserum (guinea pig) diluted to a final concentration of 1:400,000
was used as primary antibody. The secondary antibody was
purchased from Equitech-Bio, Inc. and was diluted to a final
concentration of 1:25. The assay has a sensitivity of 2.0 ng/ml and
less than 0.5% cross-reactivity with other pituitary hormones. The
intra-assay and inter-assay coefficients of variation are 6.9% and
13.3%, respectively. LH was measured in serum by a modified
supersensitive two-site sandwich immunoassay [24–25] using
monoclonal antibodies MAB1 against bovine LH and TMA
(Medix Kauniainen, Finland) against the human LH-beta subunit,
as described previously [24]. The tracer antibody, (kindly provided
by Dr. Janet Roser, Department of Animal Science, University of
California, Davis) [26] was iodinated by the chloramine T method
and purified on Sephadex G-50 columns. The capture antibody
was biotinylated and immobilized on avidin-coated polystyrene
beads (7 mm; Nichols Institute, San Juan Capistrano, CA). Mouse
LH reference preparation provided by Dr. A.F. Parlow, and the
National Hormone and Peptide program was used as standard.
The assay has a sensitivity of 0.07 ng/ml, and the average intra-
assay and inter-assay coefficients of variation for the Quality
Controls are 3.6% and 9.2%, respectively. The concentrations of
estradiol-17b (E2) and progesterone (P4) were measured in sera
with commercially available radioimmunoassay kits according to
the manufacturer’s instructions (Diagnostic Laboratories Inc.,
Webster, TX). The sensitivity for E2 assay was 4.7 pg/ml and the
intra-assay coefficients of variation (CVs) were 5.3, 5.3, and 3.2%
for low, medium and high E2 containing samples, respectively.
The inter-assay CVs for E2 assay for the aforementioned samples
were 8.1, 9.3 and 8.1%, respectively. The sensitivity for P4 assay
was 0.1 ng/ml and the intra-assay CVs were 6.4, 3.3, 5.6% for
low, medium and high P4-containing samples and the inter-assay
CVs for the above mentioned samples containing P4 were 2.4, 1.7,
and 3.3%, respectively.
RNA isolation, cDNA synthesis and gene expression
Tissues were collected from treated and control animals
immediately after they were sacrificed, snap-frozen, and stored
at 270uC until further processing. Total RNA was extracted from
ovarian and follicular tissue using the RNeasy Mini Kit (QIAGEN,
Inc., Valencia, CA) according to the manufacturer’s protocol.
Reverse-transcriptase generation of cDNA was performed with
0.5–1 mg of total RNA using an Omniscript reverse transcriptase
kit (QIAGEN) with Oligo-dT primer according to the manufac-
turer’s protocols. Subsequent PCR analysis was carried out on
40 ml of the cDNA, and the products were analyzed by
electrophoresis on a 1% agarose gel. Primer sequences for FSHR
product were as follows: (F) 59-TCTCCTTGCTGGCATTCT-
TG-39 and (R) 59-CAAGACATCATTCTGAGAGATCTCTA-
39. This primer set specifically amplified a 230 bp region of FSHR
gene, which is deleted in FORKO animal models.
Statistical analysis
Data are presented as the mean 6 SEM and were analyzed by
Student t-test with a Fischer least square difference (LSD) post hoc
test using P#0.05 as the level of significance.
Results
Daily vaginal smear
A day after IV injection of BMSCs, treated animals started to
show changes in vaginal smears. They kept showing these changes
throughout the experiment, however, the changes were not as
regular as normal animals, i.e. longer or shorter than a normal
estrus cycle. All cycles of diestrus, proestrus, estrus and metestrus
were observed in treated animals, while cyclicity in control animals
remained unchanged throughout the experiment.
Donor cells tracking
Using specific primer sets for normal and mutated FSHR
alleles, PCR amplification showed a normal allele band in (2/2)
animals treated by BM cells from (+/+) donors in all tested organs,
including brain, lung, heart, liver, spleen, ovary, uterus, vagina
and femur, while the control group of (2/2) recipients injected
with (2/2) donor BM did not show this normal FSHR allele in
any tested organs. Mutated allele was also detected in (+/+)
recipients transplanted with BM cells from (2/2) donor (Fig. 1).
Searching for oocytes and corpora lutea formation and
pregnancy
Ova were not detected in ovuductal flushing of either the
control or the treated FORKO mice, indicating that the observed
BMT-induced resumption in folliculogenes, based on increases in
serum estrogen concentrations, was not accompanied by ovula-
tion.
At different time points of the experiment, treated and control
animals were subjected to PMSG-hCG injection and mated with
age-related normal males, but no pregnancies occurred in either
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microscopically examined oviducts for possible oocyte release, but
no oocytes were found in either treated or control group. The
ovary histology survey showed the absence of corpora lutea in
either group.
Total body and organ weights
Significant increase in total body weight was observed in treated
animals compared to control animals at different time points of
treatment (P,0.03, Fig. 2A). All organs were weighed at each time
point of animal sacrifice. Reproductive organs, which are highly
modulated both structurally and functionally by estrogen, showed
remarkable increase in weight at all time points of the experiment.
Statistical analysis revealed P,0.04 for ovary, uterus, vagina and
cervix for treated vs. control animals (Fig. 2B, C, and D), while
changes in weight of other organs, including brain, lung, heart,
liver, spleen, was not statistically significant (data not shown). We
have not seen any signs of GVHD in any transplanted mice,
because all animals used in this study were immunologically
compatible.
Hormonal changes
FORKO female mice have a high level of serum FSH, a drastic
increase of at least 15-fold, compared to normal mice [14] because
of the lack of the regulatory feedback at the level of FSHR. As
shown in Fig. 3A, the serum FSH level decreased 40–50% in
treated animals at different time points (P,0.03). In FORKO
animals, estrogen is lower than normal. We observed a 4–5.5 fold
increase in the level of serum estrogen in treated animals,
compared to control animals (P,0.004, Fig. 3B). Changes of
progesterone and LH in the serum of treated and control groups
were not statistically significant (data not shown).
Follicular growth
Female FORKO mice have an overall reduced size of the
ovaries and fail to develop antral follicles [27]. In our BM treated
animals, both the total number of follicles and the number of
antral follicles were significantly higher than control animals. On
average, 2864 follicles/ovary were observed in the BM treated
group, of which 862 follicles were at the antral stage, while only
662 follicles were observed in the control group, with almost no
follicles at the antral stage (Fig. 4). These data indicate that IV
injection of BM cells stimulates ovarian folliculogesis to the antral
stage, but not to the final ovulation. Corpus luteum was not
observed in any animals. We maintained both treated and control
groups with age- matched males at all steps of the experiment for
possible ovulation and pregnancy, but pregnancy was not
observed.
FSHR expression
RNA extracted from the ovaries and other organs of treated and
control animals showed that FSHR is exclusively expressed in the
ovaries of treated animals at different time points. Expression of
FSHR was not observed in other organs from the treated groups
and bands were absent in the ovaries or other organs of control
groups (Fig. 4). The expression of FSHR in treated animals
explains the reduction of serum FSH.
Discussion
We have shown here that cells extracted from the BM of normal
syngeneic mice grafted to a preclinical FSHR knock-out mouse
model (FORKO) stimulate follicular maturation to the antral
stage, increase E2 production, decrease FSH secretion, and
express FSHR mRNA in the ovary. Several investigators have
Figure 1. Amplified DNA from different tissues of animals transplanted by (+/+)o r( 2/2) donors.
doi:10.1371/journal.pone.0032462.g001
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treated (Tr) Vs control (Ct) animals at different time points of experiment. For B, C and D organs weight considered as % of total body
weight. Both treated and control group had increase in total body weight but BMT group showed significantly more increase than control group (A,
P,0.03). As indicated, reproductive organs which are highly modulated by estrogen, showed remarkable increase in weight at all time points of the
experiment except for the first week (for B, C, and D, a P value of less than 0.04 obtained). Bone marrow transplanted animals compare to untreated
controls showed 40–50% decrease in serum FSH level (E, P,0.03) and 4–5.5 folds increase in serum estrogen (F, P,0.004) at all time points of
experiment.
doi:10.1371/journal.pone.0032462.g002
Figure 3. Development of the ovary in BMT animal (A) compared to untreated control animal (B). Both the total number of follicles and
the number of antral follicles are significantly higher in BMT compare to control group. Histological evaluation showed on average 2864 follicles/
ovary in treated group with 862 follicles at the antral stage compared to only 662 with no follicles at antral stage in untreated control mice. Photos
have been taken at the same magnification.
doi:10.1371/journal.pone.0032462.g003
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of different disorders, although the mechanisms of action remain
unknown and controversial. Some investigators claim that these
cells differentiate, while others claim that the cells may fuse with
the existing native cells, improving function of these cells by
contributing their own genetic and cellular materials. Our
experiments were not designed to address differentiation vs.
fusion. Further experiments are clearly necessary to elucidate the
exact mechanisms by which stem cells improve organ function.
Our study supports the existence of stem cells in adult mammalian
female’s bone marrow that can influence ovarian function, even
though BM transplantations in our experiment did not yield
mature eggs following natural or induced ovulation. Regular
ovulatory menstrual cycles come about via the coordination
between the hypothalamus, pituitary, ovary, and lower reproduc-
tive tract. Normal female reproductive function requires an intact
hypothalamic-pituitary unit, functional ovaries and a normally
responsive uterus [28]. The murine estrous cycle generally lasts 4–
5 days and can be divided into four stages called proestrus, estrus,
metestrus, and diestrus. Characteristic features of specific phases,
as described by Rugh et. al. [29], were as follows: a smear
consisting almost exclusively of leukocytes depicted diestrus; a thin
smear of equal numbers of leukocytes and elongated nucleated
epithelium indicated proestrus; large cornified epithelial cells were
exclusively found in estrus; and metestrus was marked by a thick
smear composed of equal numbers of nucleated epithelial cells and
leukocytes. Mice enter the estrus stage in the early hours of the
night. Circulating levels of E2 peak prior to ovulation, which
occurs at estrus, while P4 levels rise during metestrus and diestrus,
and then decline from proestrus to estrus [30,31]. Our animal
model carries a mutation in FSHR gene, which lacks any response
of granulosa cells to FSH. The stem cells engrafted in our
experimental model made granulosa cells responsive to FSH.
However, in vitro formation of granulosa cells from embryonic
and skin stem cells has been reported in two different studies
[32,33]. In these studies, the authors provided evidence of estradiol
biosynthesis and expression of FSHR in response to FSH in the
follicles derived from skin stem cells. In a more recent study [34],
the expression of FSHR in Sertoli cells by bone marrow
transplantation in male mice with testicular failure has been
reported. Another study has shown that premature ovarian failure
and infertility observed in chemotherapy-conditioned adult female
mice can be rescued by the transplantation of BM from non-
treated adult female donors [17]. The functional unit within the
ovary is the follicle, which consists of germ cells that become ova,
and granulosa and theca cells, which produce steroid hormones.
Due to the structural and functional interdependence within the
follicle between the sex hormone-producing cells and the oocyte,
insults that damage the endocrine cells lead to germ cell failure
and infertility [28]. Mutations in the FSHR gene have been
reported as a cause for primary ovarian failure (POF). Primary
ovarian failure, also known as resistance ovarian syndrome (ROS),
is a heterogeneous disorder characterized by amenorrhea and
infertility in a normal karyotype female with an elevated serum
level of follicle-stimulating hormone (FSH) and a decrease level of
estrogen. We and other investigators have shown that bone
marrow stem cells (BMSCs) are promising grafts for the treatment
of a variety of diseases, including reproductive dysfunction [15–
17]. The phenotype of FSHR (2/2) mouse, FORKO, is a good
model to study human ROS. Female (2/2) mice have elevated
serum levels of FSH, decreased E2 levels and are sterile, because of
the absence of folliculogenesis at the primary follicle stage. These
mice display thin uteri and small nonfunctional ovaries. The
objective of our study was to determine the effects of bone marrow
transplantation (BMT) on reproductive physiology of this animal
model. Interestingly, the treated animals showed estroidogenic
changes in the daily vaginal smears, 24 hrs after BMT, while
vaginal smears in all control animals remained unchanged.
Reproductive organs which are highly modulated by estrogen,
both structurally and functionally, showed remarkable increase in
weight at all time points of the experiment. Significant increase in
both the maturation and the total number of the follicles in treated
animals compared to control animals was observed. The peak
follicles/ovary was observed at 3 and 6 weeks post BMT. In the
study by Balla et.al. [27] regarding the dynamics of ovarian
development in the FORKO mice, the authors studied ovaries of
FORKO mice at different ages and concluded a postnatal and
perinatal deficit consequent to FSH receptor ablation. They
provided data that showed the total number of follicles was
significantly lesser (P,0.05) in 2-day-old FORKO ovary com-
pared to normal wild type counterpart. At 10 days of age, the total
number of follicles was significantly reduced in the FORKOs
compared with the wild types (P,0.05). These differences were
spread across different developing follicle stages. They concluded
that there was an age dependent change in the number of follicles
in the FORKO ovary relative to the normally developing follicles
in the wild type. Thus it would be conceivable that reintroducing a
functioning FSHR would support an increase in size as well as
number of ovarian follicles and prevent reduction the number of
follicles in ovary. FSH level dropped to 40–50% and serum level of
estrogen increased 4–5.5 times in treated animals compared to
control animals. We detected the expression of FSHR mRNA in
the ovaries of treated animals, while expression was not observed
in other organs.
Conclusion
Our results prove that intravenously injected bone marrow cells
stimulate the ovaries of female FSHR (2/2) FORKO mice to
express FHSR gene, restore follicular maturation and steroid
hormone production. Even though treated females did not ovulate
and, even after mating with age-matched males, did not conceive,
the ultimate goal of the treatment of infertility, our experiment has
set the stage for subsequent efforts in the treatment of this type of
infertility in humans, which currently has no effective treatment.
Further work is ongoing in our laboratory to better characterize
Figure 4. mRNA expression of FSHR gene in the ovaries of
treated and control animals and in non-reproductive organs
(liver) at two different time points (1 and 12 weeks). As shown,
FSHR mRNA is only expressed in the ovaries of BM treated animals and
there is no mRNA expression in the ovary of untreated and in non-
reproductive organs of treated group.
doi:10.1371/journal.pone.0032462.g004
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modalities.
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